Interferon Gamma Released Assay (IGRA) Segment to Dominate North America Latent TB Detection Market During 2020–2027
According to The Insight Partners market research study on “North America Latent TB Detection Market to 2027 – COVID-19 Impact and Regional Analysis and Forecast by Test and End User” is expected to reach US$ 748.25 million by 2027 from US$ 513.29 million in 2020. The market is estimated to grow at a CAGR of 5.5% from 2020 to 2027. The report provides trends prevailing in the North America latent TB detection market along with the drivers and restraints pertaining to the market growth. Growing prevalence of tuberculosis and increasing government initiatives to promote tuberculosis detection are the major factor driving the growth of the North America latent TB detection market. However, presence of multidrug resistant tuberculosis (MDR-TB) hinders the growth of North America latent TB detection market.
In case of COVID-19, North America is highly affected specially the US. North America has been witnessing a growing number of COVID-19 cases since its outbreak. As per the CDC, In the US, up to 13 million people may have latent tuberculosis infection. Testing for and treating LTBI is the most effective way to prevent TB infection. Recommended by the CDC, IGRA technology is the required method of TB testing for US Citizenship and Immigration Services (USCIS) immigration exams. The COVID-19 pandemic has threatened the national TB programs worldwide. The WHO have also notified that pandemic is threatening to reverse global progress against tuberculosis. The US is also being affected by the COVID-19 with regards to TB management. CDC’s Division of Tuberculosis Elimination (DTBE) funds 61 state, local, and territorial tuberculosis programs in the US through the TB Elimination and Laboratory cooperative agreement. In April 2020, as part of routine monitoring, CDC communicated with 50 of the 61 (82%) grantees to estimate the effect of COVID-19 on essential TB activities. The observations suggested that the COVID-19 response is diverting resources from essential TB elimination activities. The COVID-19 response has affected multiple sectors of public health, recommended preventive screening, and clinical care in the region. In some TB centers (Mexico), the hospital patient intake system was modified to support COVID-19 admissions, thus severely hindering TB services. In some centers, screening for LTBI was considered a lower priority than screening for COVID-19.
The North America latent TB detection market has been segmented into the test, end user, and country. Based on test, the market has been segmented into tuberculin skin test (TST) and interferon gamma released assay (IGRA). The interferon gamma released assay (IGRA) segment dominated the North America latent TB detection market in 2019 and same segment is expected to be fastest growing during forecast period. Based on end user, the market has been segmented into the hospitals, diagnostic centers, laboratories, and others. The hospitals segment dominated the North America latent TB detection market in 2019 and same segment is expected to be fastest growing during forecast period. Based on country, the market has been segmented into the US, Canada, and Mexico.
Abbott; ARKRAY, Inc.; BD; bioMerieux SA; F. HOFFMANN-LA ROCHE LTD.; Lionex GmbH; Oxford Immunotec Ltd; QIAGEN; and Serum Institute of India Pvt. Ltd. are among the leading companies in the North America latent TB detection market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2020, The Oxford Immunotec Ltd has received approval from the FDA to allow use of the T-SPOT.TB test in two years of age and older. This will help in meeting the pediatric patients needs for TB management.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com